Description of Medical Service
Tisagenlecleucel is an autologous, murine anti-CD19 Chimeric Antigen Receptor T cell (CAR-T) therapeutic process, involving harvesting, modifying, expanding and re-infusing a patient's own immune T-cells, to target and destroy certain cancerous cells.
Description of Medical Condition
Diffuse Large B-Cell Lymphoma (DLBCL) is an aggressive and common subtype of Non-Hodgkin Lymphoma (NHL).
Reason for Application
Medical Service Type
Hybrid health technology
Previous Application Number1519
Feedback and comments are welcome at any stage during the MSAC process. Please provide comments on Application 1519.1 via a maximum
of two A4 pages to HTA@health.gov.au
(making sure that you type the application number at the start of your comments and
in the subject heading of your email).
Public Summary Document
Meetings for this Application
13 June 2019